Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 19/20 | 1.00 |
| ▸ | PRKCA | P17252 | 7/20 | 0.82 |
| ▸ | EGFR | P00533 | 4/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376340 | 1.00 | TOP1 (1.00) | TOP1PRKCAEGFR | |
| SCHEMBL26843410 | 0.88 | TOP1 (0.85) | TOP1PRKCAEGFR | |
| SCHEMBL29435340 | 0.88 | TOP1 (1.00) | TOP1PRKCAEGFR | |
| SCHEMBL8500119 | 0.88 | TOP1 (1.00) | TOP1PRKCAEGFR | |
| SCHEMBL8769934 | 0.86 | TOP1 (1.00) | TOP1PRKCAEGFR | |
| SCHEMBL6623957 | 0.86 | TOP1 (1.00) | TOP1PRKCAEGFR | |
| SCHEMBL8032333 | 0.80 | TOP1 (0.77) | TOP1PRKCAEGFR | |
| SCHEMBL26846447 | 0.79 | TOP1 (0.87) | TOP1PRKCAEGFR | |
| SCHEMBL26846490 | 0.70 | PRKCA (0.65) | TOP1PRKCAEGFR | |
| SCHEMBL8829470 | 0.69 | TOP1 (0.56) | TOP1PRKCAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140227221-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | PROLEXYS PHARMACEUTICALS, INC. (US) | 2014-08-14 | — | — | US | claimed |
| US-20070231379-A1 | Liposome-entrapped topoisomerase inhibitors | SLATER JAMES L | 2007-10-04 | — | — | US | disclosed |
| US-7244449-B2 | Liposome-entrapped topoisomerase inhibitors | ALZA CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20050106231-A1 | Liposome-entrapped topoisomerase inhibitors | SLATER JAMES L (US) | 2005-05-19 | — | — | US | disclosed |
| US-20030133973-A1 | Liposome-entrapped topoisomerase inhibitors | SLATER JAMES L (US) | 2003-07-17 | — | — | US | disclosed |
| EP-1121102-B1 | LIPOSOME-ENTRAPPED TOPOISOMERASE INHIBITORS | ALZA CORP (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6465008-B1 | FOR THERAPY OF TUMORS | ALZA CORPORATION | 2002-10-15 | — | — | US | disclosed |
| US-20020146450-A1 | Liposome-entrapped topoisomerase inhibitors | ALZA CORPORATION | 2002-10-10 | — | — | US | disclosed |
| US-6355268-B1 | FOR CANCER CHEMOTHERAPY | ALZA CORPORATION | 2002-03-12 | — | — | US | disclosed |
| EP-1087801-B1 | TOPOISOMERASE INHIBITORS FOR PREVENTION OF RESTENOSIS | QUANAM MEDICAL CORP (US) | 2002-01-16 | — | — | EP | disclosed |
| US-20020004679-A1 | Topoisomerase inhibitors for prevention of restenosis | QUANAM MEDICAL CORPORATION | 2002-01-10 | — | — | US | disclosed |
| WO-2000064917-A2 | SYNTHETIC INDOLOCARBAZOLE REGIOISOMERS AND USES THEREOF | ADVANCED LIFE SCIENCES INC. (US) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227221-A1 | METHODS OF TREATING MULTIPLE MYELOMA AND RESISTANT CANCERS | MCL1, BCL3, DDIT3 | TOP1 72/4885PRKCA 1389/4885EGFR 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.